CPG 7909 Injection in Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small Cell Lung

In brief

Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every other treatment cycle until disease progression.

Key facts

Study ID

NCT00070629

Run by

Pfizer

People needed

116

Starts

2003-05-01

Expected to finish

2007-07-01

Last updated by the study team

2009-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed non-small cell lung cancer that is beyond surgical cure or that is metastatic (Stage IIIB or IV according to AJCC).
• Patients must have measurable disease according to the RECIST criteria.

You may not qualify if…

• Prior treatment with chemotherapy; patients may have received prior radiotherapy.
• Patients with suspected or known CNS metastases.

Where it is running

• Office of Ronald Yanagihara — Gilroy, California, United States
• Kenmar Research Institute, LLC — Los Angeles, California, United States
• Comprehensive Cancer Center of the Dessert — Palm Springs, California, United States
• Florida Cancer Specialist — Fort Myers, Florida, United States
• Indiana Hematology and Oncology Associates — Indianapolis, Indiana, United States
• Medical Center Vincennes — Vincennes, Indiana, United States
• Kentucky Cancer Clinic — Hazard, Kentucky, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Southeast Nebraska Hematology Oncology Consultants, PC — Lincoln, Nebraska, United States
• VA New Jersey Health Care System — East Orange, New Jersey, United States
• HemOnCare — Brooklyn, New York, United States
• Cancer Care of Western North Carolina — Asheville, North Carolina, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• Cancer Care Institute of Carolina — Aiken, South Carolina, United States
• Charleston Hematology/Oncology, PA — Charleston, South Carolina, United States
• The Family Cancer Center — Collierville, Tennessee, United States
• Marshfield Clinic — Marshfield, Wisconsin, United States
• Queen Elizabeth II Health — Halifax, Nova Scotia, Canada
• Ottawa Regional Cancer Center — Ottawa, Ontario, Canada
• McGill University — Montreal, Quebec, Canada
• Staedtisches Krankenhaus Martha-Maria — Halle-Dolau, Germany
• Universitätsklinikum Mannheim der Universität Heidelberg — Heidelberg, Germany
• St. Vincentius-Kliniken gAG, Hamatologie-Onkologie — Karlsruhe, Germany
• Klinikum Rechts der Isar — München, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.